Treasurer of the State of North Carolina Purchases 94,957 Shares of Johnson & Johnson $JNJ

by · The Cerbat Gem

Treasurer of the State of North Carolina lifted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 8.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,234,945 shares of the company’s stock after acquiring an additional 94,957 shares during the quarter. Johnson & Johnson accounts for 0.6% of Treasurer of the State of North Carolina’s portfolio, making the stock its 23rd largest position. Treasurer of the State of North Carolina’s holdings in Johnson & Johnson were worth $188,638,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Clark Asset Management LLC raised its position in Johnson & Johnson by 51.6% during the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after acquiring an additional 3,025 shares in the last quarter. Apexium Financial LP grew its stake in shares of Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after purchasing an additional 2,310 shares during the period. Avanza Fonder AB increased its holdings in shares of Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after purchasing an additional 6,566 shares in the last quarter. Winnow Wealth LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $295,000. Finally, 111 Capital boosted its holdings in Johnson & Johnson by 94.0% during the second quarter. 111 Capital now owns 12,474 shares of the company’s stock worth $1,905,000 after buying an additional 6,045 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $209.90 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $211.24. The company has a market cap of $505.71 billion, a PE ratio of 20.26, a price-to-earnings-growth ratio of 2.30 and a beta of 0.36. The stock’s 50 day simple moving average is $195.63 and its 200-day simple moving average is $176.68.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JNJ. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. Finally, HSBC reissued a “buy” rating and issued a $240.00 price target on shares of Johnson & Johnson in a research note on Wednesday. Four research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $206.30.

Check Out Our Latest Research Report on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).